Hisamitsu Pharmaceutical Co., Inc.
HTSUY · OTC
2/28/2025 | 2/28/2024 | 2/28/2023 | 2/28/2022 | |
|---|---|---|---|---|
| Revenue | $1,022,877 | $141,706,000 | $128,330,000 | $1,077,966 |
| % Growth | -99.3% | 10.4% | 11,804.8% | – |
| Cost of Goods Sold | $424,937 | $62,735,000 | $414,607 | $449,561 |
| Gross Profit | $597,940 | $78,971,000 | $541,829 | $628,405 |
| % Margin | 58.5% | 55.7% | 0.4% | 58.3% |
| R&D Expenses | $71,487 | $60,140 | $72,927 | $95,184 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $474,046 | -$60,140 | $382,440 | $449,481 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$71,487 | $65,803,000 | $0 | $0 |
| Operating Expenses | $474,046 | $65,803,000 | $455,368 | $544,665 |
| Operating Income | $123,894 | $13,167,000 | $11,599,000 | $83,740 |
| % Margin | 12.1% | 9.3% | 9% | 7.8% |
| Other Income/Exp. Net | $64,196 | $6,019,000 | $4,514,000 | $32,457 |
| Pre-Tax Income | $188,091 | $19,186,000 | $16,113,000 | $116,197 |
| Tax Expense | $41,864 | $4,754,000 | $3,987,000 | $27,740 |
| Net Income | $142,660 | $13,969,000 | $87,520 | $9,658,000 |
| % Margin | 13.9% | 9.9% | 0.1% | 895.9% |
| EPS | 0.48 | 0.32 | 0.28 | 0.27 |
| % Growth | 50% | 14.3% | 3.7% | – |
| EPS Diluted | 0.48 | 0.32 | 0.28 | 0.27 |
| Weighted Avg Shares Out | 294,448 | 307,674 | 317,360 | 324,852 |
| Weighted Avg Shares Out Dil | 294,872 | 308,012 | 317,624 | 325,080 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18,018 | $2,564,000 | $6,663 | $153,000 |
| Interest Expense | $151 | $18,000 | $112 | $20,000 |
| Depreciation & Amortization | $41,536 | $5,172,000 | $36,907 | $4,321,000 |
| EBITDA | $229,784 | $24,376,000 | $157,123 | $17,297,000 |
| % Margin | 22.5% | 17.2% | 0.1% | 1,604.6% |